Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?
Key takeaways
- Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?
- The company’s pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others.
- While we acknowledge the potential of IMCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term? Noor Ul Ain Rehman Mon, June 22, 2026 at 7:10 PM GMT+7 2 min read IMCR Immunocore Holdings plc (NASDAQ:IMCR) is one of the best small cap stocks to buy for the long term. Immunocore Holdings plc (NASDAQ:IMCR) announced on May 31 updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma, with the data presented in a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Mohammed Dar, Chief Medical Officer of Immunocore Holdings plc (NASDAQ:IMCR), stated that the data with brenetafusp in heavily pretreated advanced melanoma exhibited “consistent responses and survival even in those with poor prognosis, including patients with primary PD-1 resistance”, adding that the data also reinforces the company’s “confidence in the potential of brenetafusp at the dose of 160 mcg in combination with nivolumab in first-line advanced melanoma, in the ongoing Phase 3 PRISM-MEL-301 trial”.
The company further reported that brenetafusp monotherapy led to a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma, with management stating that the clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance.
Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company that pioneered the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company’s pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others.